Literature DB >> 1742845

Chemosensitisation of a drug-sensitive parental cell line by low-dose cyclosporin A.

P R Twentyman1, K A Wright.   

Abstract

We investigated the chemosensitisation of the parental EMT6 mouse mammary tumour cell line by low doses of cyclosporin A (CsA). This cell line has not previously been exposed to cytotoxic drugs but expresses low levels of P-glycoprotein. We produced greater than 2-fold sensitisation to doxorubicin, colchicine and vincristine using 0.084 microM (0.1 micrograms/ml) CsA. Cellular accumulation of doxorubicin and daunorubicin was also increased by this dose. In the MDR subline EMT6/AR1.0, much higher doses of CsA were required to effect optimal restoration of doxorubicin or daunorubicin accumulation. The effects of CsA on the parent line could not be increased by extended preincubation of cells with the sensitiser. These effects of CsA in the EMT6 parent cell line occur at a dose that is 1 order of magnitude lower than those previously reported to produce significant chemosensitisation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1742845     DOI: 10.1007/bf00686331

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  23 in total

1.  Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative.

Authors:  S C Rockwell; R F Kallman; L F Fajardo
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

2.  Identification of the multidrug resistance-related membrane glycoprotein as an acceptor for calcium channel blockers.

Authors:  A R Safa; C J Glover; J L Sewell; M B Meyers; J L Biedler; R L Felsted
Journal:  J Biol Chem       Date:  1987-06-05       Impact factor: 5.157

3.  Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

Authors:  W S Dalton; T M Grogan; P S Meltzer; R J Scheper; B G Durie; C W Taylor; T P Miller; S E Salmon
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

4.  Expression of a multidrug resistance gene in human cancers.

Authors:  L J Goldstein; H Galski; A Fojo; M Willingham; S L Lai; A Gazdar; R Pirker; A Green; W Crist; G M Brodeur
Journal:  J Natl Cancer Inst       Date:  1989-01-18       Impact factor: 13.506

5.  Improved cellular accumulation is characteristic of anthracyclines which retain high activity in multidrug resistant cell lines, alone or in combination with verapamil or cyclosporin A.

Authors:  H M Coley; P R Twentyman; P Workman
Journal:  Biochem Pharmacol       Date:  1989-12-15       Impact factor: 5.858

6.  Effect of cyclosporin and verapamil on the cellular kinetics of daunorubicin.

Authors:  X F Hu; M de Luise; T J Martin; J R Zalcberg
Journal:  Eur J Cancer       Date:  1990       Impact factor: 9.162

7.  Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.

Authors:  L M Slater; P Sweet; M Stupecky; S Gupta
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

8.  Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line.

Authors:  P R Twentyman; N E Fox; D J White
Journal:  Br J Cancer       Date:  1987-07       Impact factor: 7.640

9.  Response to chemotherapy of EMT6 spheroids as measured by growth delay and cell survival.

Authors:  P R Twentyman
Journal:  Br J Cancer       Date:  1980-08       Impact factor: 7.640

10.  Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin).

Authors:  P R Twentyman; J G Reeve; G Koch; K A Wright
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

View more
  1 in total

1.  The effects of cyclosporin A, tamoxifen, and medroxyprogesterone acetate on the enhancement of adriamycin cytotoxicity in primary cultures of human breast epithelial cells.

Authors:  J A Claudio; J T Emerman
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.